Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences
Immuneering rises as quarterly loss comes in below estimates
Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs
Brief: Immuneering Announces 64% Overall Survival At 12 Months In First-Line Pancreatic Cancer Patients Treated With Atebimetinib + mGnP
Brief: Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP
Brief: Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA
U.S. STOCKS ON THE MOVE-Firefly Aerospace, Salarius, Spectrum Brands
Immuneering rises after smaller-than-expected Q3 loss
Immuneering reports smaller-than-expected Q3 net loss
Brief: Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29
U.S. RESEARCH ROUNDUP- Carmax, Mirion Technologies, Valmont Industries
Brief: Immuneering Announces Pricing Of Underwritten Public Offering Of 18,959,914 Shares Of Class A Common Stock At $9.23 Per Share
Brief: Immuneering Announces Overall Survival of First-Line Pancreatic Cancer Patients Treated With Atebimetinib + mGnP
Brief: Immuneering Announces Proposed Underwritten Public Offering Of Class A Common Stock